Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227909 · ClinicalTrials.gov registry record · Phase 2
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT07227909: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07227909 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227909, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.
Interventions
- OTHER Standard of Care (SOC)
- DRUG Psilocybin (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2026-11-04 |
| Est. Completion | 2031-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227909
The ClinicalTrials.gov registry entry for NCT07227909 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care (SOC) is the first listed.
NCT07227909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227909 about?
NCT07227909 is a clinical study titled "NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy". To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.
What is the current status of trial NCT07227909?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2026-11-04. Estimated completion is 2031-01-31.
What interventions are being tested in trial NCT07227909?
The interventions under investigation include: Standard of Care (SOC) (OTHER), Psilocybin (drug) (DRUG).
Who is sponsoring clinical trial NCT07227909?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.